Sign up for our Weekly Checkup Newsletter
Blog archive

Healthcare M&A and valuation news and insights

Valuation multiples and M&A trends by healthcare segment, and notes on individual deals, published 2018 to 2026. New research is published in Insights.

2026

23

2025

40

2024

24

Soliant Acquired by Vistria for $2.5b (9.6x EBITDA)

Soliant acquired by Vistria for $2.5B at 9.6x EBITDA. Discover healthcare staffing valuation multiples and M&A insights in the sector. Soliant acquired by Vistria for $2.5B at 9.6x EBITDA. Discover healthcare staffing valuation multiples and M&A insights in the sector. Check out the article.

Scope Research's Healthcare M&A Review 2023

The Scope Research Healthcare M&A Review covers publicly announced deal volume trends from 2019 through 2023, with more detailed context for select 2023 transactions with disclosed financial information.

RiteAid Divests PBM Elixir for $575m (~6.1x EBITDA)

In a saga mirroring the turbulent fortunes of the brick-and-mortar pharmacy and PBM industries, Rite Aid swallowed a bitter pill on January 9th, 2024, reportedly receiving the bankruptcy judge's approval for a $575 million divestiture of its pharmacy benefit management (PBM) arm, Elixir Rx Solutions, to MedImpact Healthcare Systems, a large PBM solutions provider.

2023

27

Healthcare EBITDA Multiples - 2023 Overview

Scope Research maintains what we believe to be the largest and most reliable database of private healthcare M&A transactions with disclosed valuation metrics...

2022

9

2021

7

2020

7

2019

3

2018

8